Robert W. Baird Has Lowered Expectations for ICON Public (NASDAQ:ICLR) Stock Price

ICON Public (NASDAQ:ICLR) had its price target decreased by Robert W. Baird from $221.00 to $203.00 in a research report released on Tuesday,Benzinga reports. Robert W. Baird currently has a neutral rating on the medical research company’s stock.

Several other equities analysts also recently issued reports on ICLR. JPMorgan Chase & Co. cut their price target on shares of ICON Public from $280.00 to $265.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Royal Bank of Canada reissued an “outperform” rating and set a $263.00 price target on shares of ICON Public in a report on Wednesday, January 15th. Barclays cut their price target on shares of ICON Public from $275.00 to $240.00 and set an “overweight” rating for the company in a report on Friday, February 21st. Citigroup lowered their price objective on shares of ICON Public from $300.00 to $290.00 and set a “buy” rating for the company in a research report on Monday, January 6th. Finally, William Blair restated an “outperform” rating on shares of ICON Public in a research report on Tuesday, January 14th. Four research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, ICON Public currently has a consensus rating of “Moderate Buy” and a consensus target price of $279.17.

ICON Public Price Performance

NASDAQ:ICLR opened at $185.18 on Tuesday. The company has a 50-day moving average of $200.24 and a 200-day moving average of $237.92. The company has a market capitalization of $14.95 billion, a price-to-earnings ratio of 19.43, a PEG ratio of 1.86 and a beta of 1.21. ICON Public has a 52 week low of $179.50 and a 52 week high of $347.72. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.34 and a current ratio of 1.26.

ICON Public (NASDAQ:ICLR) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.41 by $0.01. ICON Public had a net margin of 9.56% and a return on equity of 11.81%. The firm had revenue of $2.04 billion during the quarter, compared to the consensus estimate of $2.04 billion. As a group, equities research analysts anticipate that ICON Public will post 13.38 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ICON Public

Several institutional investors have recently modified their holdings of ICLR. Sierra Ocean LLC acquired a new stake in shares of ICON Public during the 4th quarter worth approximately $29,000. Park Place Capital Corp grew its position in shares of ICON Public by 281.4% during the 4th quarter. Park Place Capital Corp now owns 225 shares of the medical research company’s stock worth $47,000 after buying an additional 166 shares during the period. Private Trust Co. NA grew its position in shares of ICON Public by 48.8% during the 4th quarter. Private Trust Co. NA now owns 250 shares of the medical research company’s stock worth $52,000 after buying an additional 82 shares during the period. GAMMA Investing LLC grew its holdings in ICON Public by 64.0% during the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after purchasing an additional 169 shares during the period. Finally, Horizon Investments LLC grew its holdings in ICON Public by 534.0% during the fourth quarter. Horizon Investments LLC now owns 653 shares of the medical research company’s stock valued at $137,000 after purchasing an additional 550 shares during the period. Institutional investors and hedge funds own 95.61% of the company’s stock.

ICON Public Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.